Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25699180 | 0.80 | L3MBTL1 (0.39) | L3MBTL1MAPT | |
| SCHEMBL12044714 | 0.79 | FGFR3 (0.33) | — | |
| SCHEMBL24391223 | 0.78 | FGFR1 (0.35) | L3MBTL1MAPT | |
| SCHEMBL26498591 | 0.78 | FGFR1 (0.35) | L3MBTL1MAPT | |
| SCHEMBL22702289 | 0.78 | FGFR1 (0.35) | L3MBTL1MAPT | |
| SCHEMBL24506368 | 0.70 | L3MBTL1 (0.39) | L3MBTL1MAPT | |
| SCHEMBL18821184 | 0.68 | DPP4 (0.39) | L3MBTL1MAPT | |
| SCHEMBL2625814 | 0.68 | DPP4 (0.39) | L3MBTL1MAPT | |
| SCHEMBL18883354 | 0.68 | DPP4 (0.39) | L3MBTL1MAPT | |
| SCHEMBL18556394 | 0.68 | L3MBTL1 (0.39) | L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090298806-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298806-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | L3MBTL1 3511/4885MAPT 3722/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | L3MBTL1 3511/4885MAPT 3722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.